Study Determined Association Between Risk of Melanoma, Aspirin Use

Study Determined Association Between Risk of Melanoma, Aspirin Use

In a review of nearly 200,000 patients from a Midwest metropolitan area, researchers sought to determine if chronic aspirin use would offer the same risk reduction for melanoma as has been seen in various cancers.

Hope, Optimism Reduce Psychological Distress in Advanced Cancer

Hope, Optimism Reduce Psychological Distress in Advanced Cancer

A cross-sectional analysis evaluated the impact of hope and optimism on different facets of psychological distress among patients with advanced melanoma, colorectal, lung, or gastrointestinal cancers.

Prognostic Indicator for Cutaneous Melanoma: SNLB vs Breslow Thickness

Prognostic Indicator for Cutaneous Melanoma: SNLB vs Breslow Thickness

Investigators sought to compare the prognostic value of sentinel lymph node status vs Breslow thickness in patients with cutaneous melanoma.

Presence of Iris Pigmented Lesions Indicates Melanoma Risk

Presence of Iris Pigmented Lesions Indicates Melanoma Risk

The likelihood for development of cutaneous melanoma may be greater for individuals with iris pigmented lesions, according to a study.

Age Not a Deterrent to Immunotherapy for Malignant Melanoma

Age Not a Deterrent to Immunotherapy for Malignant Melanoma

Investigators sought to evaluate whether age is associated with risk for immune-related adverse events among patients with metastatic melanoma treated with immunotherapy.

Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma

Adjuvant Vemurafenib Does Not Improve Disease-Free Survival in Melanoma

Researchers report on finding of a double-blind phase 3 study on the efficacy of adjuvant vemurafenib in patients with resected stage IIC to IIIB melanoma.

Induced Pluripotent Stem Cell Vaccine May Help Prevent Tumor Growth

Induced Pluripotent Stem Cell Vaccine May Help Prevent Tumor Growth

iPSC vaccine prevented tumor growth in syngeneic murine breast CA, mesothelioma, melanoma models

Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma

Obesity, Male Gender May Improve Survival Outcomes with Targeted and Immunotherapy in Melanoma

A retrospective study evaluated the relationship of BMI with survival outcomes among patients with metastatic melanoma who received targeted therapy, immunotherapy, or chemotherapy.

FDA Upgrades Nivolumab to Regular Approval for Adjuvant Treatment of Advanced Melanoma

FDA Upgrades Nivolumab to Regular Approval for Adjuvant Treatment of Advanced Melanoma

The FDA granted approval for nivolumab for adjuvant treatment of some patients with melanoma, based on the results of the CHECKMATE-238 study.

Potential for Metastatic Melanoma Cure Seen in High CR Rate With Pembrolizumab

Potential for Metastatic Melanoma Cure Seen in High CR Rate With Pembrolizumab

Baseline tumor size and PD-L1 status were independently associated with the likelihood of a complete response.

Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma

Distinct Patterns of Shiny White Streaks Strong Indicator of Melanoma

Patients presenting with lesions with shiny white streaks on dermoscopy should undergo biopsy for possible melanoma.

Melatonin Derivatives Exhibit Cytotoxic Activity in Melanoma and Breast Cancer

Melatonin Derivatives Exhibit Cytotoxic Activity in Melanoma and Breast Cancer

Melatonin and its analogues, in addition to their ability to regulate circadian rhythms, may exhibit cytotoxic activity via various cellular mechanisms.

No Increased Risk for Melanoma in Patients With MM

No Increased Risk for Melanoma in Patients With MM

An increased prevalence of melanoma has been observed in patients with various immunocompromised conditions.

Researchers Find No Link Between Acne and Malignant Melanoma in Men

Researchers Find No Link Between Acne and Malignant Melanoma in Men

Individuals categorized as overweight or obese had a significantly increased risk for malignant melanoma.

Survival Benefit in Advanced Melanoma With Pembrolizumab Versus Ipilimumab

Survival Benefit in Advanced Melanoma With Pembrolizumab Versus Ipilimumab

Fifty-five percent of patients treated with pembrolizumab survived through 24-months compared with 43% of patients treated with ipilimumab.

Challenging the Standard of Care in Advanced Melanoma: Focus on Pembrolizumab

Challenging the Standard of Care in Advanced Melanoma: Focus on Pembrolizumab

[Cancer Management and Research] This study examines the advances that pembrolizumab has made in melanoma and upcoming research that may further improve melanoma treatment.

Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy

Case Report of a KIT-mutated Melanoma Patient With an Excellent Response to Apatinib and Temozolomide Combination Therapy

[OncoTargets and Therapy] This article examines a case of metastatic melanoma in which the patient had an excellent response to apatinib/TMZ combination therapy with progression-free survival for more than one year.

Overall Survival Increase for Melanoma Brain Metastases

Overall Survival Increase for Melanoma Brain Metastases

Median overall survival from time of diagnosis has increased from 7.5 to 22.7 months in the last decade.

Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination

Overall Survival in Advanced Melanoma Improved With Nivolumab, Ipilimumab Combination

Overall survival was significantly prolonged in patients with advanced melanoma who were treated with nivolumab plus ipilimumab compared with either drug alone, according to results from the Checkmate 067 study.

Risk of Some Cancers Higher in Women With a History of Periodontal Disease

Risk of Some Cancers Higher in Women With a History of Periodontal Disease

A study on a cohort of women enrolled in the WHI-OS shows that those with a history of periodontal disease had a higher risk for developing some cancers.

Awareness of Genomic Risk for Melanoma May Increase Conversations With Family, Health Care Providers

Awareness of Genomic Risk for Melanoma May Increase Conversations With Family, Health Care Providers

Awareness of personal genetic risk for melanoma may prompt patients to discuss cancer risk with family and health care professionals, and make lifestyle changes.

FDA Expands Ipilimumab Indication to Include Pediatric Unresectable or Metastatic Melanoma

FDA Expands Ipilimumab Indication to Include Pediatric Unresectable or Metastatic Melanoma

The FDA approved the indication expansion for ipilimumab based on evidence from 2 clinical trials evaluating its safety and efficacy in pediatric patients.

Melanoma Diagnoses Can Vary Widely Among Pathologists

Melanoma Diagnoses Can Vary Widely Among Pathologists

When researchers sent sample slides to pathologists for review, the assessments varied widely and some pathologists even disagreed with their own initial assessment when retested months later.

Adjuvant Bevacizumab Does Not Increase Survival in High-Risk Melanoma

Adjuvant Bevacizumab Does Not Increase Survival in High-Risk Melanoma

Five-year survival rate found similar to observation despite a significant improvement in disease-free interval.

Higher-Dose Adjuvant Ipilimumab More Toxic, Does Not Improve Recurrence-Free Survival

Higher-Dose Adjuvant Ipilimumab More Toxic, Does Not Improve Recurrence-Free Survival

Study of patients with resected high-risk melanoma reveals higher rates of treatment-related adverse events with 10 vs 3 mg/kg.

Cancer Recurrence Fear Reduced by Novel Psychological Intervention

Cancer Recurrence Fear Reduced by Novel Psychological Intervention

'Conquer Fear' decreased fear among survivors of breast and colorectal cancer and melanoma compared with relaxation techniques.

Biopolymer Delivery of Synergistic Immunotherapy Could Improve Efficacy

Biopolymer Delivery of Synergistic Immunotherapy Could Improve Efficacy

Biopolymer codelivery of CAR T cells and stimulator of IFN genes directly to the surface of solid tumors more effectively reduced tumor size.

Noninvasive 2-Gene Test Helps Distinguish Melanoma From Nonmelanoma

Noninvasive 2-Gene Test Helps Distinguish Melanoma From Nonmelanoma

Two-gene pigmented lesion test classifies skin lesions as melanoma or nonmelanoma, helping with diagnostic challenges faced with the visual image and pattern recognition approach.

Assessment of Melanoma Screening Practices Produces Data-Driven, Risk-Based Guidelines

Assessment of Melanoma Screening Practices Produces Data-Driven, Risk-Based Guidelines

Dermatologist assessment of screening practices addresses the lack of a national consensus on screening guidelines for melanoma.

Psoriasis May Increase Risk of Melanoma and Hematologic Cancers

Psoriasis May Increase Risk of Melanoma and Hematologic Cancers

Patients with psoriasis had 1.53 times greater risk of developing a malignancy, regardless of the type of psoriasis therapy they are receiving.

Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma

Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma

Whole-exome sequencing of tumor biopsies explain low response rate to immunotherapy in metastatic melanoma.

Kinase Inhibitors: Managing Adverse Effects in the Treatment of Metastatic Melanoma

Kinase Inhibitors: Managing Adverse Effects in the Treatment of Metastatic Melanoma

Despite their efficacy in metastatic melanoma, KIs include risk of serious side effects in patients. This overview explains the effects and management recommendations for 4 agents used to treat metastatic melanoma.

Dabrafenib + Trametinib Rechallenge Active in Pretreated Melanoma

Dabrafenib + Trametinib Rechallenge Active in Pretreated Melanoma

Rechallenge with dabrafenib plus trametinib demonstrated antitumor activity in patients who had previously progressed on BRAF inhibitor therapy.

Antidiabetes Drug Holds Promise as Adjuvant Therapy for Older Patients with Melanoma

Antidiabetes Drug Holds Promise as Adjuvant Therapy for Older Patients with Melanoma

Rosiglitazone has potential for older patients with melanoma who develop resistance to targeted therapies.

Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated

Cost-Effectiveness of Immunotherapy for Advanced Melanoma Evaluated

Researchers sought to conduct a cost-effectiveness analysis of immunotherapy for patients with advanced melanoma.

Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer

Pembrolizumab Active Against Rare Melanoma, Extends Survival in Bladder Cancer

Clinical trials show pembrolizumab active against mucosal melanoma, extends survival in bladder cancer.

Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline

Trends in Behaviors, Medical Practice Indicate Mortality From Melanoma Will Decline

Using statistical models, predictions were made for death rates from melanoma in 3 three countries and based on availability of a treatment.

Computer 'Deep Learning' Algorithm Matches Dermatologists at Classifying Melanomas

Computer 'Deep Learning' Algorithm Matches Dermatologists at Classifying Melanomas

Researchers compared the ability of an artificial-intelligence algorithm to recognize and classify skin cancers with the clinical evaluations of dermatologists.

IFN Induction No Better Than Observation for Intermediate-risk Melanoma

IFN Induction No Better Than Observation for Intermediate-risk Melanoma

Induction therapy with intravenous interferon α-2b appeared to be no better than observation alone for the management of patients with intermediate-risk melanoma.

Customers Find Useful Information in Results from Direct-to-Consumer Genetic Testing

Customers Find Useful Information in Results from Direct-to-Consumer Genetic Testing

Results of a series of Internet surveys revealed customers' perceptions of harms, benefits, and limitations of genetic information received from direct-to-consumer genetic testing.

Beach Umbrella Not Enough for Protection from UV Rays

Beach Umbrella Not Enough for Protection from UV Rays

Comparison studied the effectiveness of sun protection offered by a beach umbrella alone with that of sunscreen with a high sun protection factor.

Melanoma Incidence Still on the Rise in Parts of the United States

Melanoma Incidence Still on the Rise in Parts of the United States

Melanoma incidence varies by region, and many states have experienced an increase.

Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma

Alcohol Consumption, Particularly White Wine, Associated With Increased Risk of Melanoma

A review of data from three large, prospective studies examined a potential association between alcoholic beverage consumption and risk of melanoma.

Study Identifies Factors Associated With Outcomes After Dabrafenib + Trametinib

Despite the effectiveness of dabrafenib in combination with trametinib for metastatic BRAF-mutant melanoma, many patients experience disease progression that often leads to death. In this data analysis, researcher sought to identify clinical factors associated with long-term response and survival.

PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

PD-1 Inhibitors Ideal for First-Line Therapy in Treatment-Naïve Advanced Melanoma

Atlhough survival for patients with advanced melanoma is similar with both targeted therapies and immunotherapies, a review of the literature reveals why one of them may be a better choice as first-line therapy.

Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment

Immune Checkpoint-Related Neurotoxicity May Be More Common During Combination Treatment

Neurotoxicity is not uncommon in patients with melanoma treated with immune checkpoint inhibitors. In this study, therefore, researchers sought to examine the incidence of neurotoxicity across anti-CTLA-4 and anti-PD-1 antibodies at a single institution.

More Than Half of Melanomas Are Self-Detected, Especially by Women

More Than Half of Melanomas Are Self-Detected, Especially by Women

More melanomas are self-detected by women; men tend to have more melanomas in less visible locations.

Psychoeducational Intervention Effective for Reducing Fear of Melanoma Recurrence

Psychoeducational Intervention Effective for Reducing Fear of Melanoma Recurrence

A newly developed, evidence-based psychoeducational intervention effectively reduced fear of cancer recurrence and stress in patients at high risk for developing another melanoma.

HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma

HRQoL Better Maintained With Pembrolizumab in Ipilimumab-refractory Melanoma

Treatment with pembrolizumab better maintained health-related quality of life compared with chemotherapy in patients with advanced melanoma refractory to ipilimumab.

Experimental Drug Shows Promise in Melanoma Treatment

Experimental Drug Shows Promise in Melanoma Treatment

Pevonedistat was effective for inhibiting proliferation of melanoma cell lines in vitro, research indicates.

Supportive Care Needs Assessed in Localized Cutaneous Melanoma

Supportive Care Needs Assessed in Localized Cutaneous Melanoma

Patients with localized melanoma see their supportive care needs peak at their initial cancer diagnosis and if they experience disease recurrence.

Study Supports Use of PD-1 Inhibitors in Acral, Mucosal Melanomas

Response rates with PD-1 inhibitors in patients with acral and mucosal melanomas were similar to previously reported rates in patients with cutaneous melanoma.

Some Gene Variants Increase the Risk for Melanoma in People With Red Hair, Freckling

Some Gene Variants Increase the Risk for Melanoma in People With Red Hair, Freckling

Variants of the MC1R gene, associated with red hair, pale skin, and freckles, increases the number of genetic mutations related to skin cancer and the level of other gene mutations, further increasing the risk for skin cancer.

Data Confirm Benefit of Cobimetinib and Vemurafenib in Melanoma

Cobimetinib in combination with vemurafenib as a standard first-line approach improves survival in patients with BRAF V600 mutation-positive melanoma, updated results of the coBRIM study.

USPSTF: Evidence Lacking to Recommend Full-body Skin Cancer Screens

USPSTF: Evidence Lacking to Recommend Full-body Skin Cancer Screens

New report doesn't change Task Force's prior statement on skin cancer screening issued in 2009

Training Primary Care Providers to Screen for Melanoma Increases Diagnoses, With Little Affect on Dermatology Visits or Skin Surgeries

Training Primary Care Providers to Screen for Melanoma Increases Diagnoses, With Little Affect on Dermatology Visits or Skin Surgeries

Training primary care providers (PCP) to detect early melanoma led to increased melanoma diagnoses, but had little impact on skin surgeries or dermatology visits.

The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care

The Melanoma MAICare Framework: A Microsimulation Model for the Assessment of Individualized Cancer Care

[Cancer Informatics] In this research, a microsimulation model framework is used to examine the impact of simultaneously altering curative treatment approaches in different phases of melanoma treatment.

Study Better Characterizes Immunotherapy-related Skin Toxicities

Patients receiving PD-1 or PD-L1 antibodies exhibited papular and nodular eruptions with scale, as well as mucosal lesions with lichenoid features, that were typically manageable with topical steroid treatment.

De Novo Melanomas May Be More Aggressive Than Nevus-associated Lesions

De novo melanomas, which arise from clinically normal skin with no associated nevus, may be more aggressive than nevus-associated melanomas.

Nivolumab Maintains Baseline HRQoL in Advanced Melanoma

Nivolumab Maintains Baseline HRQoL in Advanced Melanoma

In addition to improving overall survival compared with dacarbazine in patients with advanced melanoma, nivolumab maintains baseline levels of health-related quality of life to ultimately confer long-term quality of survival benefit.

Primary Care Melanoma Screening Does Not Cause Major Adverse Consequences

Primary Care Melanoma Screening Does Not Cause Major Adverse Consequences

Population-based screening for melanoma performed by primary care providers does not cause substantial harm with respect to skin surgeries and dermatology visits.

Outcomes Are Not Improved With Pegylated Interferon Alpha-2a vs Interferon Alpha-2a

Outcomes Are Not Improved With Pegylated Interferon Alpha-2a vs Interferon Alpha-2a

PEG-IFN did not improve improve outcomes for patients with melanoma compared with IFN. Furthermore, patients receiving PEG-IFN were more likely to discontinue treatment due to toxicity.

Disease-Free Status Is Achieved by Combining Immunotherapy Treatments in Patient With Metastatic Melanoma

A patient with refractory metastatic melanoma was successfully treated with a novel combination of 2 different types of immunotherapy.

Soles of the Feet Should Also Be Checked for Skin Cancer

Soles of the Feet Should Also Be Checked for Skin Cancer

Cutaneous melanoma is rare on feet, but often advanced at point of diagnosis.

Melanoma: Pembrolizumab Better Than Ipilimumab Regardless of PD-L1 Expression

Melanoma: Pembrolizumab Better Than Ipilimumab Regardless of PD-L1 Expression

Pembrolizumab provides benefit over ipilimumab in patients with advanced melanoma, regardless of tumor PD-L1 expression status or number of prior therapies, a study presented at the 2016 ASCO Annual Meeting has shown.

Modified Thiazole Benzenesulfonamide Demonstrates Anticancer Activity in Melanoma

A newly discovered synthesized drug reduced the viability of melanoma cells without affecting normal cells in cell culture and mouse xenograft models of the disease. The drug, HA15, is a type of thiazole benzenesulfonamide.

Follow-up Data Confirm Pembrolizumab as Standard of Care for Advanced Melanoma

Follow-up Data Confirm Pembrolizumab as Standard of Care for Advanced Melanoma

Final analysis of data from the phase 3 KEYNOTE-006 presented at the ASCO 2016 Annual Meeting confirm the superiority of pembrolizumab over ipilimumab for advanced melanoma.

Pembrolizumab Demonstrates Long-Term Survival in Advanced Melanoma

Pembrolizumab Demonstrates Long-Term Survival in Advanced Melanoma

At 3 years, 40% of patients with advanced melanoma treated with pembrolizumab are alive regardless of whether they had been treated with ipilimumab or not, follow-up results from the KEYNOTE-001 study reported at the ASCO 2016 Annual Meeting.

Dabrafenib Plus Trametinib Continue to Show Survival Benefit in BRAF-mutant Metastatic Melanoma

Dabrafenib Plus Trametinib Continue to Show Survival Benefit in BRAF-mutant Metastatic Melanoma

The longest overall survival follow-up among randomized phase 3 trials evaluating BRAF and MEK inhibitors in patients with BRAF-mutant metastatic melanoma to date has shown the best 3-year outcome with dabrafenib plus trametinib to be in patients with normal LDH and fewer than 3 disease sites, according to a presentation at the ASCO 2016 Annual Meeting.

Binimetinib: New Treatment Option for NRAS-Mutant Cutaneous Melanoma Before/After Immunotherapy?

Binimetinib: New Treatment Option for NRAS-Mutant Cutaneous Melanoma Before/After Immunotherapy?

Binimetinib may represent a new effective therapy for patients with NRAS-mutant melanoma, both before and after immunotherapy. That is the conclusion of the phase 3 NEMO study, results of which were presented at the ASCO 2016 Annual Meeting.

Pembrolizumab Improves Long-term Survival in Advanced Melanoma

Pembrolizumab Improves Long-term Survival in Advanced Melanoma

Four in 10 patients with newly diagnosed and previously treated advanced melanoma were alive 3 years after initiating pembrolizumab.

Combination of Radiation and Immunotherapy Shows Promise in Melanoma

Combination of Radiation and Immunotherapy Shows Promise in Melanoma

Combining radiation treatments with a new generation of immunotherapies is showing promise in the treatment of melanoma, according to a recent review.

Liquid Biopsy Found Comparable to Standard Tissue Biopsy in Identifying BRAF V600 Mutation Status

Plasma from a blood draw can be used to test for BRAF V600 mutations in advanced cancers in just 90 minutes, and results were comparable to using tissue biopsy.

CDK4/6 Inhibitor Allows Sustained Dosing for Targeted Inhibition in 5 Solid Tumor Cancer Types

CDK4/6 Inhibitor Allows Sustained Dosing for Targeted Inhibition in 5 Solid Tumor Cancer Types

Abemaciclib, an investigational cancer therapeutic, showed durable clinical activity as a continuous single-agent therapy, according to results of a phase 1 trial with 5 tumor-specific cohorts.

A Protein Could Predict the Response to Immunotherapy in Metastatic Melanoma

A Protein Could Predict the Response to Immunotherapy in Metastatic Melanoma

The Bim protein might predict which patients could be successfully treated with immunotherapy for metastatic melanoma.

ATS: Aggressive Melanoma Linked to Untreated Sleep Apnea

ATS: Aggressive Melanoma Linked to Untreated Sleep Apnea

New study highlights the importance of diagnosing and treating obstructive sleep apnea because of possible cancer connection.

Developments in Intralesional Therapy for Metastatic Melanoma

Developments in Intralesional Therapy for Metastatic Melanoma

[Cancer Control] This research explores the efficacy of intralesional therapy as a treatment option for patients with unresectable, locally advanced, or metastatic melanoma.

Pembrolizumab Achieves Response and Increased Survival in Melanoma

Pembrolizumab Achieves Response and Increased Survival in Melanoma

Overall objective responses occurred in one-third of patients with melanoma who were treated with pembrolizumab in a phase 1b clinical trial.

SPF30 Sunscreens Delay Melanoma in Preclinical Model

SPF30 Sunscreens Delay Melanoma in Preclinical Model

Melanoma onset was delayed by applying sun protection factor 30 (SPF30) sunscreen prior to exposure to ultraviolet-B light in a mouse model of the disease.

Study Pools Data to Evaluate Melanoma Outcomes After Pembrolizumab

Study Pools Data to Evaluate Melanoma Outcomes After Pembrolizumab

Among patients with advanced melanoma, the human PD-1-blocking antibody pembrolizumab was associated with an overall objective response rate of 33%, 12-month progression-free survival rate of 35%, and median overall survival of 23 months.

Melanoma Tumor Cells Respond Differently to Therapy in Elderly Patients Than in Younger Patients

Melanoma Tumor Cells Respond Differently to Therapy in Elderly Patients Than in Younger Patients

Therapy for the elderly with melanoma may be affected by findings that aged tumor cells in melanoma behave differently than younger tumor cells.

Sun Exposure Beneficial Despite the Risk of Melanoma

Sun Exposure Beneficial Despite the Risk of Melanoma

Though sunbathers are at an increased risk of developing skin cancer, women who sunbathe are likely to live longer than those who avoid the sun.

Microneedle Patch Delivers Localized Immunotherapy for Melanoma

Microneedles embedded in a patch deliver cancer immunotherapy treatment directly to the site of melanoma, according to preliminary findings in animal studies.

MC1R Variants May Increase Melanoma Risk, Even Without Sun Exposure

MC1R Variants May Increase Melanoma Risk, Even Without Sun Exposure

Variant of gene linked to skin pigmentation may be tied to higher melanoma risk.

Higher Mole Count Doesn't Always Correspond to Higher Melanoma Risk

Higher Mole Count Doesn't Always Correspond to Higher Melanoma Risk

Physicians shouldn't rely on mole count as the only reason to perform skin exams for melanoma.

HIV Drug Could Re-sensitize Therapy-resistant Melanoma

HIV Drug Could Re-sensitize Therapy-resistant Melanoma

The expression of the PAX3 and MITF genes in melanoma can cause early, nonmutational, reversible drug resistance; tissues that express these genes can then later develop mutational, irreversible drug resistance. The HIV drug nelfinavir can prevent this resistance.

Prognosis Poor for Women With Pregnancy-Associated Melanoma

Prognosis Poor for Women With Pregnancy-Associated Melanoma

Among women aged up to 49 years with a pregnancy-associated melanoma, recurrence rates were higher than seen in other groups.

Melanoma Therapy Associated With Cutaneous Events

Melanoma Therapy Associated With Cutaneous Events

Anti-programmed cell death-1 therapy tied to lichenoid reactions, eczema, vitiligo

Biomarker for Class 1 Uveal Melanoma Correlates with Metastatic Disease

Biomarker for Class 1 Uveal Melanoma Correlates with Metastatic Disease

A new biomarker measurement might improve the accuracy of prognostic testing and precision medicine in uveal melanoma.

Conventional Criteria May Underestimate Response to Treatment in Advanced Melanoma

Conventional Criteria May Underestimate Response to Treatment in Advanced Melanoma

RECIST v1.1 may underestimate the treatment response in patients with advanced melanoma treated with pembrolizumab.

Fewer Total Nevi, More Atypical Nevi Linked With Thick Melanomas in Younger Patients

Fewer Total Nevi, More Atypical Nevi Linked With Thick Melanomas in Younger Patients

Among younger patients, thick melanomas may be commonly found in those with fewer total nevi but more atypical nevi.

PRAME in Class 1 Uveal Melanoma Predicts Metastasis

PRAME in Class 1 Uveal Melanoma Predicts Metastasis

PRAME mRNA expression is independent prognostic biomarker in Class 1 uveal melanoma.

Melanoma Visualized in Live Zebrafish From Origin of First Cancer Cell To Metastasis

Melanoma Visualized in Live Zebrafish From Origin of First Cancer Cell To Metastasis

Researchers visualized the origins of cancer from the first affected cell through its spread in a live animal: the zebrafish. This research may change scientific understanding of melanoma and other cancers leading to new treatments that can be administered before the cancer has taken hold.

Interferon Has Little Benefit for Patients With Small Amounts of Melanoma in the Lymph Nodes

Interferon Has Little Benefit for Patients With Small Amounts of Melanoma in the Lymph Nodes

No evidence that interferon is necessary or helpful in cases of melanoma with minimal metastasis to the lymph nodes, according to the final results of the Sunbelt Melanoma Trial.

Treatment Goals Separate From Life Goals Among Patients With Advanced Cancer

Treatment Goals Separate From Life Goals Among Patients With Advanced Cancer

Patients with advanced cancer view life goals as distinct from and less important than treatment goals, according to a recent study.

Earlier and More Frequent Tanning Bed Use by Women Associated With Melanoma Incidence and Age at Diagnosis

Earlier and More Frequent Tanning Bed Use by Women Associated With Melanoma Incidence and Age at Diagnosis

Younger age at first use and more frequent use of indoor tanning beds are largely responsible for the steep increase in melanoma diagnoses in women younger than 40 years.

Inherited Genetic Markers Predictive of Survival Prognosis for Patients with Melanoma

Inherited Genetic Markers Predictive of Survival Prognosis for Patients with Melanoma

Prognosis for patients with cutaneous melanoma may be predicted by an inherited genetic marker providing a personalized tool to gauge a person's survival and determine if closer monitoring is needed in the years following surgery.

Prognosis Is Poor for Women With Pregnancy-Associated Melanoma

Prognosis Is Poor for Women With Pregnancy-Associated Melanoma

A recent study showed that women younger than 50 years who are pregnant or were recently pregnant at diagnosis of melanoma have a higher risk of death from the skin cancer.

Improved Progression-Free, Overall Survival Achieved With Dabrafenib, Trametinib Combo in Melanoma

Improved Progression-Free, Overall Survival Achieved With Dabrafenib, Trametinib Combo in Melanoma

Dabrafenib plus trametinib achieves good overall and progression-free survival in BRAF inhibitor-naïve patients with melanoma.

Using Mouse Avatars Aids Identification of Effective Targeted Therapies for Patients With Melanoma

Using Mouse Avatars Aids Identification of Effective Targeted Therapies for Patients With Melanoma

Using xenograft mice as avatars of patients with melanoma, scientists demonstrated that a previously ineffective targeted drug may halt disease progression in certain patients.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs